Celltrion Pharm (Korea) Investor Sentiment

068760 Stock  KRW 59,800  1,300  2.13%   
About 62% of Celltrion Pharm's investor base is looking to short. The analysis of current outlook of investing in Celltrion Pharm suggests that many traders are alarmed regarding Celltrion Pharm's prospects. The current market sentiment, together with Celltrion Pharm's historical and current headlines, can help investors time the market. In addition, many technical investors use Celltrion Pharm stock news signals to limit their universe of possible portfolio assets.
  
over two weeks ago at news.google.com         
Celltrion to retire 400 mn treasury stock in January - Korea Economic Daily
Google News at Macroaxis
over a month ago at news.google.com         
Korea faces challenges in achieving MSCI ambitions amid shrinking index presence -
Google News at Macroaxis
over three months ago at news.google.com         
Celltrion Pharm launches three biosimilars in Korea -
Google News at Macroaxis
over three months ago at news.google.com         
Why Celltrions Retail Investors Oppose the Merger with Celltrion Pharm -
Google News at Macroaxis
over six months ago at news.google.com         
Celltrion Holdings pushing for listing on Nasdaq sources -
Google News at Macroaxis
over six months ago at news.google.com         
Celltrion completes merger with Celltrion Healthcare - The Korea JoongAng Daily
Google News at Macroaxis
over a year ago at news.google.com         
Celltrion posts record earnings in Q3, buoyed by upbeat biosimilar ... - The Investor
Google News at Macroaxis
over a year ago at news.google.com         
Celltrions Q3 profit jumps on strong demand for biosimilar ... - Yonhap News Agency
Google News at Macroaxis
over a year ago at news.google.com         
Short selling ban raises hopes for biotech stocks rise - KBR
Google News at Macroaxis
over a year ago at news.google.com         
Celltrion to push for additional merger with affiliate Celltrion Pharm ... - Yonhap News Agency
Google News at Macroaxis
over a year ago at news.google.com         
Celltrion, Inc. Celltrion Healthcare Co., Ltd. Announce ... - Joplin Globe
Google News at Macroaxis
over a year ago at news.google.com         
Seoul shares hit 7-month low on US rate hike woes - The Korea Herald
Google News at Macroaxis
over a year ago at news.google.com         
Celltrion Expands Access To YUFLYMA Adalimumab-Aaty ... - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
European Commission Approves First Aflibercept Biosimilar - The Center for Biosimilars
Google News at Macroaxis
over a year ago at news.google.com         
Seoul shares snap 4-day losing streak ahead of key economic data - The Korea Herald
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Celltrion Pharm that are available to investors today. That information is available publicly through Celltrion media outlets and privately through word of mouth or via Celltrion internal channels. However, regardless of the origin, that massive amount of Celltrion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Celltrion Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Celltrion Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Celltrion Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Celltrion Pharm alpha.

Celltrion Pharm Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Celltrion Stock analysis

When running Celltrion Pharm's price analysis, check to measure Celltrion Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celltrion Pharm is operating at the current time. Most of Celltrion Pharm's value examination focuses on studying past and present price action to predict the probability of Celltrion Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celltrion Pharm's price. Additionally, you may evaluate how the addition of Celltrion Pharm to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios